"Adoption of Targeted and Epigenetic Therapies"
-
- One significant trend in the Sézary Syndrome market is the increasing adoption of targeted agents and epigenetic modulators, which show promise in difficult-to-treat CTCL subsets
- The need for long-term disease control and reduced toxicity is driving interest in HDAC inhibitors and monoclonal antibodies with selective activity
- For instance, recent studies have highlighted the improved progression-free survival achieved with brentuximab vedotin in patients with CD30-positive variants of Sézary Syndrome
- This shift is transforming the treatment landscape toward precision oncology, with focus on patient genotype and disease stage
- Advancements in companion diagnostics and treatment monitoring tools are further supporting the trend of early and tailored therapeutic intervention
- A key trend is increased investment in next-generation agents that target genetic drivers of T-cell dysregulation in Sézary Syndrome. Clinical trials on dual-action HDAC and immune checkpoint inhibitors are ongoing
